Integra Lifesciences Holdings (IART) Gains from Investment Securities (2014 - 2026)

Integra Lifesciences Holdings has reported Gains from Investment Securities for 13 years, with the latest figure at $519000.0 in Q2 2026.

• Quarterly Gains from Investment Securities rose 1365.85% year-over-year to $519000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$21.9 million (down 180.84% YoY) and the FY2025 annual result came in at -$21.3 million, down 268.31% from the prior year.
• Gains from Investment Securities rose to $519000.0 in Q2 2026 per IART's latest filing, from -$1.3 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $4.7 million in Q1 2023 and troughed at -$14.4 million in Q3 2025.
• A 5-year average of -$2.0 million and a median of -$463500.0 in 2022 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2022 and 2026: Gains from Investment Securities plunged 8505.03% in 2022, then jumped 1365.85% in 2026.
• Over 5 years, Gains from Investment Securities stood at -$823000.0 in 2022, then surged by 660.15% to $4.6 million in 2023, then plunged by 218.7% to -$5.5 million in 2024, then declined by 22.17% to -$6.7 million in 2025, then soared by 107.76% to $519000.0 in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $519000.0, -$1.3 million, and -$6.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.